NYSE · Health care

Kairos Pharma, LTD. (KAPA)

It posted a net loss of $5.8M. At June 30, 2026 it held $2.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

What Kairos Pharma, LTD. does

Kairos Pharma, LTD. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker KAPA.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$5.6M	-$5.4M	-$0.30	n/a
2024	n/a	-$2.3M	-$2.6M	-$0.23	n/a
2024	n/a	-$1.7M	-$1.8M	-$0.17	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Kairos Pharma, LTD. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Investor disclosure 8-K
August 21, 2026
Shareholder rights changed 8-K
August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.06 versus -$0.08.
July 22, 2026
Material agreement 8-K
July 15, 2026
Other event 8-K
June 30, 2026
Shareholder vote results 8-K
June 4, 2026
Other event 8-K
May 26, 2026
Additional proxy material DEFA14A
May 22, 2026
Annual report to shareholders ARS
May 22, 2026
Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on December 30, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about KAPA

What does Kairos Pharma, LTD. do?

Kairos Pharma, LTD. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker KAPA.

Is Kairos Pharma, LTD. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $5.8M.

When did Kairos Pharma, LTD. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 14, 2026.

Similar companies

Compare KAPA with

Compare KAPA with any company

Follow KAPA

Get an email when Kairos Pharma, LTD. files with the SEC: results, executive changes, material agreements and annual reports.

Follow KAPA: get an email when it files

Where the numbers come from

Financial figures are the values Kairos Pharma, LTD. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.